Corporate ActionMay 22, 2026, 04:37 PM
Akari Therapeutics to Raise $5.5M in Private Placement
AI Summary
Akari Therapeutics Plc entered into a securities purchase agreement to raise approximately $5.5 million in gross proceeds through a private placement. The company will sell 1,470,588 unregistered American Depository Shares (ADSs) or prefunded warrants, along with Series H, I, and J warrants, to certain investors. The net proceeds are intended for working capital and general corporate purposes, with the offering expected to close in three tranches by July 15, 2026.
Key Highlights
- Akari Therapeutics to raise approximately $5.5 million in gross proceeds from a private placement.
- Offering includes 1,470,588 unregistered ADSs or prefunded warrants, plus Series H, I, and J warrants.
- ADS Unit Purchase Price is $3.74; Pre-Funded Unit Purchase Price is $3.739.
- Placement agent, Paulson Investment Company, LLC, to receive a 2% cash fee and 117,647 ADSs.
- Net proceeds will be used for working capital and general corporate purposes.
- Issuance of Series Warrants and Placement Agent ADSs is subject to shareholder approval.
- Gross proceeds will be funded in three tranches, with the final closing expected by July 15, 2026.
Price Impact
More from AKTX